tbuckley/cabot-search huggingface dataset:
TCT-41 Invasive Assessment of Coronary Flow Reserve In Severe Aortic Stenosis With Normal Coronary Arteries
Authors: Alejandro Gutierrez-Barrios, Sergio Gamaza-Chulián, Dolores Ruiz-Fernandez, Antonio Agarrado, Jesus Oneto, Javier Benezet
Journal: Journal of the American College of Cardiology (2015)
Colorectal anastomotic dehiscence: an endoscopic modified-stent solution
Authors: Antonino Granata, Gabriele Curcio, Dario Ligresti, Ilaria Tarantino, Luca Barresi, Davide Cintorino, Mario Traina
Journal: Endoscopy (2016)

A 64-year-old man with multiple comorbidities (obesity and metabolic syndrome, dilated cardiomyopathy, type 2 diabetes mellitus, chronic renal insufficiency, obstructive sleep apnea syndrome, and colonic diverticula) underwent anterior resection for distal rectal cancer with protective ileostomy. A few days later, enteral juice was flowing from surgical drains; an urgent endoscopy with fluoroscopy showed the presence of a small (8-mm) anastomotic leak, which was managed conservatively. At 1-month follow-up, endoscopy showed a 75 % anastomotic dehiscence with intraluminal migration of a drain ([Fig. 1]). The patient's clinical condition worsened and, after multidisciplinary discussion, an endoscopic transanastomotic fully covered metal stent placement was planned.
A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.
Authors: Christopher P Venner, Thirusha Lane, Darren Foard, Lisa Rannigan, Shameem Mahmood, Simon DJ Gibbs, Jennifer Pinney, Sanjay Banypersad, Jason Dungu, Carol Whelan, Helen Lachmann, Julian D Gillmore, Philip N Hawkins, Ashutosh Wechalekar
Journal: Blood (2012)
Ultrasociality without group selection: Possible, reasonable, and likely
Authors: Max M. Krasnow
Journal: Behavioral and Brain Sciences (2016)

It is uncontroversial that humans are extremely social, and that cultures have changed over time. But, the evidence shows that much of the social psychology underlying these phenomena (1) predates the agricultural transition, and (2) is not the result of group selection. Instead, this psychology appears intricately designed to capture social gains when possible in our complex ancestral social ecology.
Transcription Factor ZBP-89 Drives a Feedforward Loop of β-Catenin Expression in Colorectal Cancer
Authors: Bryan E. Essien, Sinju Sundaresan, Ramon Ocadiz-Ruiz, Aaron Chavis, Amy C. Tsao, Arthur J. Tessier, Michael M. Hayes, Amanda Photenhauer, Milena Saqui-Salces, Anthony J. Kang, Yatrik M. Shah, Balazs Győrffy, Juanita L. Merchant
Journal: Cancer Research (2016)

In colorectal cancer, APC-mediated induction of unregulated cell growth involves posttranslational mechanisms that prevent proteasomal degradation of proto-oncogene β-catenin (CTNNB1) and its eventual translocation to the nucleus. However, about 10% of colorectal tumors also exhibit increased CTNNB1 mRNA. Here, we show in colorectal cancer that increased expression of ZNF148, the gene coding for transcription factor ZBP-89, correlated with reduced patient survival. Tissue arrays showed that ZBP-89 protein was overexpressed in the early stages of colorectal cancer. Conditional deletion of Zfp148 in a mouse model of Apc-mediated intestinal polyps demonstrated that ZBP-89 was required for polyp formation due to induction of Ctnnb1 gene expression. Chromatin immunoprecipitation (ChIP) and EMSA identified a ZBP-89-binding site in the proximal promoter of CTNNB1 Reciprocally, siRNA-mediated reduction of CTNNB1 expression also decreased ZBP-89 protein. ChIP identified TCF DNA binding sites in the ZNF148 promoter through which Wnt signaling regulates ZNF148 gene expression. Suppression of either ZNF148 or CTNNB1 reduced colony formation in WNT-dependent, but not WNT-independent cell lines. Therefore, the increase in intracellular β-catenin protein initiated by APC mutations is sustained by ZBP-89-mediated feedforward induction of CTNNB1 mRNA. Cancer Res; 76(23); 6877-87. ©2016 AACR.
TCT-808 Evaluation of the Multilayer Flow Modulator in the Management of Complex Thoracoabdominal Aortic Pathology: A Systematic Review and Metaanalysis
Authors: Niamh Hynes, Ala Elhelali, Edel P. Kavanagh, Patrick Delassus, Liam Morris, Sherif Sultan
Journal: Journal of the American College of Cardiology (2015)
Identification of Actionable Genomic Alterations Across Different Lymphoma Histologies Using a Comprehensive Next Generation Genomic Sequencing Clinical Assay
Authors: Connie Batlevi, Craig H. Moskowitz, Andrew D. Zelenetz, Steven M. Horwitz, Lia Palomba, John F. Gerecitano, Amanda R. M. Copeland, Paul Hamlin, Matthew J. Matasar, Craig S. Sauter, Alison J Moskowitz, Ariela Noy, David J. Straus, Carol S Portlock, Colleen Mazzei, Janine D. Pichardo, Vincent Miller, Phil J Stephens, Jie He, Julie T Feldstein, Ross L. Levine, Ahmet Dogan, Anas Younes
Journal: Blood (2014)
Reduced Relapse Risk In Patients With AML After Hhcmv-Replication Post Transplantation-First Results Of a Prospective Registration Trial
Authors: Ahmet H. Elmaagacli, Nina-Kristin Steckel, Meltem Kekec, Rudolf Trenschel, Markus Ditschkowski, Tanja Gromke, Sandra Christoph, Hellmut Ottinger, Dietrich Beelen, Michael Koldehoff
Journal: Blood (2013)
FLT3-ITD and Age Are the Major Prognostic Factors In Relapsed AML with Normal Karyotype
Authors: Jürgen Krauter, Katharina Wagner, Frederik Damm, Felicitas Thol, Walter Fiedler, Oliver G. Ottmann, Wolfgang F.W. Heit, Michael Lübbert, Aruna Raghavachar, Gudrun Göhring, Michael Heuser, Brigitte Schlegelberger, Gerhard Heil, Arnold Ganser
Journal: Blood (2010)
TCT-801 Surgical versus Endovascular Treatment for Acute Limb Ischemia: A Systematic Review and Meta-Analysis of Clinical Trials
Authors: Jad Omran, Obai Abdullah, Belal Firwana, Beau Hawkins, Mazen Abu-Fadel, Christopher White, William A. Gray, Herbert Aronow, Ashraf Al-Dadah
Journal: Journal of the American College of Cardiology (2015)
Zalypsis Has Synergistic Effect When Combined with Bortezomib + Dexamethasone through Caspase Dependent and Mainly Independent Mechanisms and through A Potent Induction of DNA Damage
Authors: Enrique M. Ocio, Lorena González-Coco, Laura San-Segundo, Xi Chen, Teresa Hernández-Iglesias, Diego Fernández-Lázaro, Teresa Paíno, Mercedes Garayoa, Carmen Cuevas, Pablo Avilés, Enrique Álava, Atanasio Pandiella, J.F San Miguel
Journal: Blood (2010)
SNP-Array Karyotyping Reveals the Presence of Previously Cryptic Clonal Chromosomal Aberrations Including Segmental UPD in Patients with Fanconi Anemia.
Authors: Marcin Wlodarski, Holger Toennies, Andrew Dunbar, Zach Nearman, Marion Nagy, Joern-Sven Kuehl, Heidemarie Neitzel, Wolfram Ebell, Jaroslaw Maciejewski
Journal: Blood (2007)
Insulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance
Authors: Max C. Petersen, Anila K. Madiraju, Brandon M. Gassaway, Michael Marcel, Ali R. Nasiri, Gina Butrico, Melissa J. Marcucci, Dongyan Zhang, Abudukadier Abulizi, Xian-Man Zhang, William Philbrick, Stevan R. Hubbard, Michael J. Jurczak, Varman T. Samuel, Jesse Rinehart, Gerald I. Shulman
Journal: Journal of Clinical Investigation (2016)

Nonalcoholic fatty liver disease (NAFLD) is a risk factor for type 2 diabetes (T2D), but whether NAFLD plays a causal role in the pathogenesis of T2D is uncertain. One proposed mechanism linking NAFLD to hepatic insulin resistance involves diacylglycerol-mediated (DAG-mediated) activation of protein kinase C-ε (PKCε) and the consequent inhibition of insulin receptor (INSR) kinase activity. However, the molecular mechanism underlying PKCε inhibition of INSR kinase activity is unknown. Here, we used mass spectrometry to identify the phosphorylation site Thr1160 as a PKCε substrate in the functionally critical INSR kinase activation loop. We hypothesized that Thr1160 phosphorylation impairs INSR kinase activity by destabilizing the active configuration of the INSR kinase, and our results confirmed this prediction by demonstrating severely impaired INSR kinase activity in phosphomimetic T1160E mutants. Conversely, the INSR T1160A mutant was not inhibited by PKCε in vitro. Furthermore, mice with a threonine-to-alanine mutation at the homologous residue Thr1150 (InsrT1150A mice) were protected from high fat diet-induced hepatic insulin resistance. InsrT1150A mice also displayed increased insulin signaling, suppression of hepatic glucose production, and increased hepatic glycogen synthesis compared with WT controls during hyperinsulinemic clamp studies. These data reveal a critical pathophysiological role for INSR Thr1160 phosphorylation and provide further mechanistic links between PKCε and INSR in mediating NAFLD-induced hepatic insulin resistance.
Allogeneic Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) after Pretransplant 5-Azacitidine.
Authors: Teresa Field, Melissa Alsina, Ernesto Ayala, Hugo Fernandez, William Janssen, Mohammed Karfan-Dabaja, Jeffery Lancet, Mafda Melchert, Jyoti Raychaudhuri, Daniel Sullivan, Alan List, Claudio Anasetti, William Poling, Janelle Perkins
Journal: Blood (2007)
Correlation Between Bone Marrow Dysplasia and Genomic Profile in De Novo Acute Myeloid Leukemia (AML): A Study By the ALFA Group
Authors: Thomas Cluzeau, Orianne Wagner-Ballon, Thomas Boyer, Estelle Guerin, Emmanuel Benayoun, Daniel Lusina, Isabelle Garcia, Claude Gardin, Pierre Fenaux, Cecile Pautas, Bruno Quesnel, Dominique Bordessoule, Christine Terré, Xavier Thomas, Sylvie Castaigne, Aline Renneville, Claude Preudhomme, Herve Dombret
Journal: Blood (2015)
PD-1 and PD-L1 Are Overexpressed in the "Intermediate CD14+CD16+" and "Non Classical CD14lowCD16+" but Not in the "Classical CD14+CD16-" Monocytes in the Peripheral Blood of Chronic Myelomonocytic Leukemia
Authors: Hae Tha Mya, Maria Diez Campelo, Sandra Valle Herrero, Agustin Díaz-Alvarez, Domingo Bustos, Luis M Vaquero, José J Pérez, Verónica González, Jose M Bastida, Carlos Aguilar, Abelardo Bárez, Noemi Puig, Alejandro Martin-Sancho, María Jesús Garcia, Irene Aires, Sara Alonso, Marcos González, Consuelo Del Cañizo, Maria Belen Vidriales
Journal: Blood (2015)
Phosphoinositide 3'-Kinase (PI3K) Delta Inhibitor, GS-9820, Enhances Anti-Tumor Efficacy When Combined with Conventional Chemotherapeutic Agents in Primary Samples and Human Tumor Xenograft Model of Multiple Myeloma
Authors: Eric Sanchez, Mingjie Li, Cathy Wang, Haiming Chen, Dave M. Johnson, Brian J. Lannutti, James R. Berenson
Journal: Blood (2012)
Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib
Authors: Shaji K Kumar, Betsy R. Laplant, Craig B. Reeder, Vivek Roy, Francis Buadi, Morie A. Gertz, Kristina Laumann, Peter Leif Bergsagel, Angela Dispenzieri, Prashant Kapoor, Joseph Mikhael, Keith Stewart, Suzanne R. Hayman, Yi L. Hwa, Thomas E. Witzig, Sikander Ailawadhi, David Dingli, Ronald S. Go, Yi Lin, Candido E. Rivera, S. Vincent Rajkumar, Martha Q. Lacy
Journal: Blood (2015)
Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis
Authors: Rikhia Chakraborty, Thomas M. Burke, Oliver A. Hampton, Daniel J. Zinn, Karen Phaik Har Lim, Harshal Abhyankar, Brooks Scull, Vijetha Kumar, Nipun Kakkar, David A. Wheeler, Angshumoy Roy, Poulikos I. Poulikakos, Miriam Merad, Kenneth L. McClain, D. Williams Parsons, Carl E. Allen
Journal: Blood (2016)
Phase I study of daily cisplatin and concurrent radiotherapy in patients with cervical carcinoma
Authors: A. Mitsuhashi, T. Uno, N. Tanaka, K. Suzuka, S. Take, K. Yamazawa, H. Matsui, H. Ito, S. Sekiya
Journal: Journal of Clinical Oncology (2004)

5103 Background: Chemoradiation based on cisplatin is the standard treatment of locally advanced cervical carcinoma; however, the optimal scheduling, dosing were not still decision, the purpose of this study was to determine the maximum-tolerated dose (MTD) of cisplatin when administrated daily during pelvic radiation (RT). Methods: Patients with locally advanced cervical carcinoma and patients who required postoperative RT were registered. Low dose cisplatin (starting dose 6.0mg/m2, 0.5mg/m2 escalation per level) was given with daily application concurrently with RT (2Gy/ day; total dose of 50Gy). Cohorts of three patients were enrolled at each level. If one of three patients at any level developed dose-limiting toxicity (DLT), three additional patients were then treated at the same dose level. DLT was defined as grade 3/4 nonhematologic toxicity except for alopecia, nausea and vomiting, grade 3/4 neutropenia or thrombocytopenia. Cisplatin was interrupted when hematological DLT were observed.The MTD was defined as the dose level below that which produced DLT in more than one-third of treated patients. Results: Twenty-five patients were eligible in this study. In 21/25 patients (84%), cisplatin was administrated continuously as planned with no interruption. As shown in the table, the MTD was 8mg/m2 and the DLT was neutropenia. Fourteen patients were analysis for response: 11 complete response and 2 partial responses were obtained with an overall response rate of 92.9%. Conclusions: A dose of 8 mg/m2 daily was determined to be MTD and considered the recommended dose of daily cisplatin. Daily cisplatin is a well-tolerated and effective radiosensitizer in cervical carcinoma patients. No significant financial relationships to disclose.
Inosine-Triphosphate-Pyrophosphatase Genotype Is a Determinant of Severe Fever with Neutropenia Following Treatment of Acute Lymphoblastic Leukemia with Combination Chemotherapy That Includes Mercaptopurine Adjusted for Thiopurine-S-Methyltransferase Genotype.
Authors: Gabriele Stocco, Meyling Cheok, Wenjian Yang, Thierry Dervieux, Kristine Crews, Deqing Pei, Cheng Cheng, Ching-Hon Pui, Mary V. Relling, William E. Evans
Journal: Blood (2007)
Prognostic Score for Adults with Acute Myeloid Leukemia in First Complete Remission
Authors: Gevorg Tamamyan, Gautam Borthakur, Jorge E. Cortes, Farhad Ravandi, Elias Jabbour, Naval Daver, Naveen Pemmaraju, Maro Ohanian, Albert Kolomansky, Gabriele Todisco, Ce Shi, Sherry Pierce, S. Andrew Peng, Marina Konopleva, Hagop M. Kantarjian, Tapan Kadia
Journal: Blood (2015)
Systematic review: prevalence of malignancy in incidental focal thyroid nodules identified by positron emission tomography
Authors: P. Shie, A. Taur, R. Cardarelli
Journal: Journal of Clinical Oncology (2008)

6063 Background: To review current literature and tabulate the prevalence of malignancy in incidental focal or focal plus diffuse hypermetabolic thyroid lesions detected by positron emission tomography (PET). Methods: Studies evaluating the prevalence of thyroid malignancies incidentally found by PET were systematically searched for in the MEDLINE, CINAHL, EBM Review, and Cochrane Central Register of Controlled Trials, including a manual search of the references lists in all articles. Search terms used include thyroid disease, thyroid gland, thyroid neoplasm, thyroid nodule, fluorodeoxyglucose F18, PET, and incidental findings. Studies were included based on the following criteria: 1) PET performed on any human subject for work-up of various malignancies other than thyroid cancer or in healthy volunteer subjects for cancer screening, 2) focal or focal plus diffuse hypermetabolic activity in the thyroid, 3) confirmation of diagnosis by histopathologic examination. Exclusion criteria included: 1) patients with history of thyroid cancer, thyroid disease, or have undergone thyroid surgery, 2) case report or case series, 3) only diffuse activity of the thyroid were reported. Two reviewers independently reviewed the eligibility and abstracted data. Results: Sixteen retrospective studies were included, with a total of 63,499 patients. Of the 63,499 patients studied, 667 patients (1.05%, [95% confidence interval [CI]: 0.97% - 1.13%]) were found to have focal or focal plus diffuse hypermetabolic activity in the thyroid. In the group of 376 patients with further evaluation, thyroid malignancy was found in 125 patients (33.24% [95% CI: 28.50% - 38.26%]). Of the malignancies diagnosed, papillary thyroid carcinoma was found in 99 patients (79.20%, [95% CI: 71.02% - 85.94%]). The remainder of the patients were found to have follicular variant of the papillary thyroid carcinoma, 7.20%, (95% CI: 3.34% - 13.23%); follicular carcinoma, 0.80% (95% CI: 0.02% - 4.38%); and other malignancies, 13.60% (95%, CI: 8.13% - 20.88%). Conclusions: The high prevalence of thyroid malignancy associated with focal or focal plus diffuse hypermetabolic thyroid lesions found on positron emission tomography warrants further evaluation when encountered incidentally. No significant financial relationships to disclose.
Starving for attention: Malnutrition screening in a community cancer center.
Authors: Shanthi Sivendran, Patti I. Roda, Jennifer Sporay, Ronald Guittar, Christine Cox, Kristina Braine Newport
Journal: Journal of Clinical Oncology (2015)

96 Background: It is estimated that 50% of cancer patients are at risk for malnutrition, causing physical and emotional distress that interferes with cancer treatment. Early detection and intervention may prevent severe malnutrition. Assessment and management of malnutrition are included in National Comprehensive Cancer Network (NCCN) guidelines but no specific recommendation regarding screening tool selection is provided. The Malnutrition Screening Tool (MST) is a short, easily administered screening tool, validated for identification of malnutrition in cancer patients. In this study, we describe the results of MST administration in a large community cancer institute. Methods: The MST was administered during all patient visits to our cancer institute in 2015. Patients scoring 2 or higher were identified as ‘at risk’ for malnutrition, resulting in electronic dietitian referral prompts. We retrospectively reviewed MST results from April through June 2015 and compared to dietitian referrals during the same period in 2014. At that time, dietitian consults were prompted by physician referral, patient request, or triggered by NCCN distress thermometer screen. Results: The MST identified 84% more patients in need of dietitian referral in 2015 compared to usual care in 2014. From April through June 2015, the MST was administered during 4082 discrete patient encounters. 6.7% of these visits resulted in MST score of 2 or greater for a total of 193 ‘at risk’ patients in need of referral to dietitian. Weight loss of 2 pounds or greater was reported by patients in 16% of encounters. Eating poorly because of a decreased appetite was reported by patients in 13% of the encounters. From April through June 2014, 105 patients were referred for dietitian consult, indicating the MST identified 88 more ‘at risk’ patients. Conclusions: The MST is a simple, valid tool for malnutrition screening in cancer patients that resulted in an 84% increase in identification of ‘at risk’ patients. This tool should be considered for standard malnutrition screening of cancer patients, to prompt referral for dietitian intervention.
NF-κB/TNF-α Positive Feedback Loop with Active Proteasome Machinery Supports Myeloid Leukemia Initiating Cell Capacity
Authors: Yuki Kagoya, Akihide Yoshimi, Shunya Arai, Keisuke Kataoka, Masahiro Nakagawa, Keiki Kumano, Mineo Kurokawa
Journal: Blood (2012)
Apoptosis Induced by Extracts of Helleborus Niger in Different Lymphoma and Leukemia Cell Lines and Primary Lymphoblasts of Children with ALL Is Independent of Smac-Overexpression and Executed Via the Mitochondrial Pathway.
Authors: Patrick Jesse, Gritt Mottke, Georg Seifert, Simone Fulda, Guenter Henze, Aram Prokop
Journal: Blood (2007)
TCT-334 Factors Affecting Quantitative Stent Assessment by Optical Frequency Domain Imaging: In Vivo Direct Comparison with Intravascular Ultrasound
Authors: Yuhei Kobayashi, Hideki Kitahara, Shigemitsu Tanaka, Kozo Okada, Takumi Kimura, Fumiaki Ikeno, Paul Yock, Peter J. Fitzgerald, Yasuhiro Honda
Journal: Journal of the American College of Cardiology (2015)
Phase I/II trial of weekly doxorubicin (Doxo)/docetaxel (Doce) followed by hormone ablation (HA) in recurrent prostate cancer (PC)
Authors: H. Mannuel, N. Dawson, C. Guo, B. Dorsey, M. Besche, J. Smoot, C. Engstrom, A. Hussain
Journal: Journal of Clinical Oncology (2004)

4765 Background: For PC pts with PSA failure after surgery (RP) and/or XRT no standard treatments are established. An approach being piloted by our group is to give chemotherapy first, then HA. We report phase I results of an ongoing phase I/II trial of weekly Doxo/Doce followed by HA in such pts. Methods: Pts with histologically documented PC with rising PSA post RP, XRT were eligible. PSA had to be > 4 ng/ml with serum testosterone (T) in non-castrate range at entry. Positive bone scans, CT scans were not an exclusion criteria. Treatment is: weekly Doxo/Doce x 4 cycles (each cycle: Doxo d1, 8, 15 IVP; Doce d1, 8, 15 IV over 30 min, q 28 d) followed by LHRH agonist + Bicalutamide 50 mg/d x 1 yr. Two dose levels of Doxo (cohort 1: 15 mg/m2 d1, 8, 15; cohort 2: 20 mg/m2 d1, 8, 15) with fixed dose Doce (30 mg/m2 d1, 8, 15) were used. Results: 16 pts have been enrolled. Baseline characteristics (medians): age 62.5 y, PSA 19.05 ng/ml, GS 7, serum T 409 ng/dl; Baseline imaging: + bone scans 4, + CT 2. 11 pts completed all 4 cycles of chemotherapy and 5 at least 2 cycles; 7 pts completed at least 4 mos of HA. 1 pt died from disease progression. In total, 11 pts are in cohort 1, 5 in cohort 2. Toxicities are (cohort 1): Gr 3/4 gpenia 4 pts, Gr 3 hyperglycemia 2, DVT 1, GI bleed 1; (cohort 2): Gr 3 gpenia 1 pt, Gr 3 febrile gpenia 1, Gr 3 hand-foot syndrome 1. So far, there have been no chemotherapy dose reductions in cohort 1, while 2 of 5 pts in cohort 2 had doses reduced. 8/11 pts (73%) completing 4 cycles chemotherapy had > 40% decrease in PSA. For pts with documented metastasis, post chemotherapy 2/4 pts with + bone scans had resolution, 1 had progression. Median T (n = 11) post 4 cycles chemotherapy: 338 ng/dl. Median PSA (n=9) post 1 mo HA: 0.5 ng/ml. Conclusions: Phase II dose for hormone-sensitive recurrent PC is Doxo 15 mg/m2 and Doce 30 mg/m2 d l, 8, 15, q 28 d. This regimen is active and well-tolerated. Pts retain hormone sensitivity post chemotherapy. Phase II component of the trial is ongoing. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis
TCT-799 Antiplatelet Prescription Trends During Lower Extremity Peripheral Artery Endovascular Interventions: Insights from the XLPAD Registry
Authors: Denizen Kocak, Kyle Planchard, Thomas M. Das, Atif Mohammad, Ehrin J. Armstrong, Nicolas W. Shammas, Osvaldo Gigliotti, Andrew Klein, Mazen Abu-Fadel, Tayo Addo, Emmanouil Brilakis, Subhash Banerjee
Journal: Journal of the American College of Cardiology (2015)